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Abstract
Background: Early diagnosis of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) has potential 
prognostic and therapeutic implications but can be difficult due to the lack of specific clinical manifestations or 
accurate non-invasive tests. Histopathologic parameters correlating with PH in IPF are also not known. Remodeling of 
postcapillary pulmonary vessels has been reported in the nonfibrotic areas of explanted lungs from IPF patients. We 
hypothesized that iron deposition and increased alveolar capillaries, the findings often seen in postcapillary PH, might 
predict the presence of clinical PH, independent of the severity of fibrosis or ventilatory dysfunction in IPF patients. To 
test this hypothesis, we examined the association between these histologic parameters and the degree of PH, with 
consideration of the severity of disease in IPF.
Methods: Iron deposition and alveolar septal capillary density (ASCD) were evaluated on histologic sections with 
hematoxylin-eosin, iron, elastin and CD34 stainings. Percentage of predicted forced vital capacity (FVC%) was used for 
grading pulmonary function status. Fibrosis score assessed on high resolution computed tomography (HRCT) was 
used for evaluating overall degree of fibrosis in whole lungs. Right ventricular systolic pressure (RVSP) by transthoracic 
echocardiography was used for the estimation of PH. Univariate and multivariate regression analyses were performed.
Results: A cohort of 154 patients was studied who had the clinicopathological diagnosis of IPF with surgical lung 
biopsies or explants during the period of 1997 to 2006 at Mayo Clinic Rochester. In univariate analysis, RVSP in our IPF 
cases was associated with both iron deposition and ASCD (p < 0.001). In multivariate analysis with FVC% and HRCT 
fibrosis score included, iron deposition (p = 0.02), but not ASCD (p = 0.076), maintained statistically significant 
association with RVSP. FVC% was associated with RVSP on univariate analysis but not on multivariate analysis, while 
fibrosis score lacked any association with RVSP by either univariate or multivariate analyses.
Conclusions: Iron deposition and ASCD in non fibrotic lung tissue showed an association with RVSP, suggesting that 
these features are possible morphologic predictors of PH in IPF.
Background
Idiopathic pulmonary fibrosis (IPF) is characterized by a
histopathologic pattern of usual interstitial pneumonia
(UIP) and progressive fibrosis without response to medi-
c a l  t h e r a p y  [ 1 ] .  H o w e v e r ,  c l i n i c a l  c o u r s e  o f  I P F  i s  n o t
always predictable despite its generally poor prognosis
[2]. Pulmonary hypertension (PH) has been postulated to
be a factor that might complicate and impact the progno-
sis of IPF [3]. Also, the therapeutic agents for PH might
be effective for those who have PH with IPF.
Early diagnosis of PH in IPF is difficult; lack of specific
clinical symptoms often leads to delayed diagnosis of PH
in IPF patients [3]. Reported prevalence of PH in IPF
patients ranges from 20 to 84% when evaluated by pul-
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monary arterial enlargement on chest radiography, right
ventricular systolic pressure (RVSP) using transthoracic
echocardiography, or mean pulmonary artery pressure
using right-heart catheterization [3-8]. Biomarkers such
as B-type natriuretic peptide (BNP) and N-terminal pro-
hormone BNP are potentially helpful tools in identifying
PH [9].
Histologic features correlating with PH in IPF are not
known. W e hypothesized that increased alveolar septal
capillaries and hemosiderin deposition, the findings often
seen in the setting of postcapillary type of PH or pulmo-
nary venous remodeling, might predict the presence of
clinical PH independent of the degree of overall fibrosis
or pulmonary function abnormalities in IPF cases.
In order to examine this hypothesis, we evaluated a
cohort of 154 IPF cases for the association between these
two histologic parameters and the right ventricular sys-
tolic pressure (RVSP) assessed by transthoracic echocar-
diography, with the consideration for the ventilatory
f u n c t i o n  s t a t u s  a s  a s s e s s e d  b y  p e r c e n t a g e  o f  p r e d i c t e d
forced vital capacity (FVC%) and for the extent of fibrosis
by fibrosis score on chest high-resolution computed
tomography (HRCT).
Materials and methods
Case selection
All patients who had a diagnosis of UIP by surgical lung
biopsy (n = 144) or by examination of explanted lungs (n
= 10) were identified during the period from 1997 to
2006. Patients with underlying collagen vascular disease
or other identifiable cause for pulmonary fibrosis were
excluded. A review of medical records was done for all
cases for pertinent clinical information. This study has
been approved by the Institutional Review Board of Mayo
Foundation.
Echocardiography
Two-dimensional transthoracic echocardiography,
pulsed and continuous-wave Doppler, and color flow
imaging were performed in all patients using previously
described techniques [6]. Right ventricular systolic pres-
sure was calculated based on the modified Bernoulli
equation and right atrial pressure was estimated as 5, 10,
15 or 20 mm Hg, on the basis of the size and respiratory
change of the inferior vena cava using previously
described techniques [6]. Right ventricular size and sys-
tolic function were scored semiquantitatively on a scale 0
(normal), 1 (mildly impaired or enlarged), 2 (moderately
impaired or enlarged), or 3 (severely impaired or
enlarged). Left ventricular dimensions and ejection frac-
tion were obtained by previously recommended tech-
niques and scored semiquantitatively on a scale 0
(normal), 1 (mildly impaired or enlarged), 2 (moderately
impaired or enlarged), or 3 (severely impaired or
enlarged) [6]. Left atrial size was scored semiquantita-
tively on a scale 0 (normal), 1 (mildly enlarged), 2 (moder-
ately enlarged), or 3 (severely enlarged).
Pulmonary function test
Spirometry was performed using a Puritan Bennett
renaissance pneumotach-based flow spirometer (Mall-
inckrodt, St Louis, MO, USA) according to the standards
set by the American Thoracic Society/European respira-
tory Society (ATS/ERS) and flows were expressed as per-
centage of predicted using the reference equations of
Crapo et al [10].
Fibrosis score
Preoperative chest HRCT scans that were performed at
the closest time point to the biopsy date or transplanta-
tion date were evaluated. If preoperative CT was not
available, the earliest chest HRCT scans following the
biopsies were reviewed. Each case was reviewed indepen-
dently by two thoracic radiologists (PWE and BJB or
TEH) and the final scores and measurements were
assigned by consensus. Percentage of pulmonary paren-
chyma replaced by fibrosis was assigned based on visual
estimation as previously described [11]. Each lung was
evaluated for percentage fibrosis that was assigned to the
nearest 5%.
Histopathologic evaluation
I n  a l l  s u r g i c a l  l u n g  b i o p s y  c a s e s,  e n t i r e  a v a i l a b l e  g r o s s
specimens were submitted for microscopic examination.
For explanted lungs, multiple sections were reviewed
from each lobe. All cases were evaluated by two pulmo-
nary pathologists (KHK and ESY) and the diagnosis of
UIP was confirmed according to the criteria outlined in
ATS/ERS International Multidisciplinary Consensus
Classification of the Idiopathic Interstitial Pneumonias
[1,12]. Verhoeff-van Gieson elastic (VVG), iron, and
CD34 stains as well as routine hematoxylin-eosin (HE)
were used for microscopic evaluation of iron deposition
and ASCD.
Measurement of alveolar septal capillary density (ASCD)
Sections were scanned for representative areas in nonfi-
brotic parenchyma at low-power field (×100 magnifica-
tion), and individual alveolar capillary counts were then
performed on high-power fields (×400 magnification)
using CD34-stained sections. ASCD was quantified in
representative alveolar capillary spots in ten nonfibrotic
lobules. ASCD was expressed by the mean of capillary
endothelial row between the alveolar epithelial layers in
these ten nonfibrotic lobules of alveolar tissue, and cate-
gorized as Grade 1 and 2 with the mean of ASCD <1.5
and ≥1.5, respectively (Figure 1). This categorization as
normal (ASCD <1.5; grade 1) and abnormal (ASCD ≥ 1.5;
grade 2) is based on the fact that there should not beKim et al. Respiratory Research 2010, 11:37
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more than one row of capillaries between the alveolar
septum with consideration tangential section [13].
Assessment of hemosiderin deposition
Sections were scanned for hemosiderin deposition by the
evaluation of iron staining at low power field (×100 mag-
nification), and confirmed at high power fields (×400
magnification) to verify the presence of chunky, refractile
hemosiderin pigments. Hemosiderin deposition was
quantified as the total number of iron-positive foci on
one representative glass slide and assigned to one of the
following categories: 0, <1; 1, 1~5; 2, 6~10; and 3, >10
(Figure 2). This grading system is a modification from a
previous study [14].
Statistics
Continuous variables were summarized using mean ±
standard deviation, median, and range; categorical vari-
ables were summarized using number and percentage.
Univariable and multivariable regression analyses were
performed to investigate the association of all variables
with RVSP. For these analyses RVSP was the dependent
variable. P-values < 0.05 were considered statistically sig-
nificant.
Results
Age of the patients ranged from 28 to 87 years (mean ±
standard deviation: 64.4 ± 10.1 years; median: 66 years)
(Table 1). Female and male patients comprised 40.3% and
59.7%, respectively (Table 1). There was no association
between age and iron deposition or age and ASCD
(Spearman's correlation coefficients -0.14 [p = 0.099) and
-0.13 [p = 0.16], respectively).
Assessment of iron deposition was possible in 149 cases
of the cohort and showed the following results: grade 0 in
67 cases, grade 1 in 41 cases, grade 2 in 24 cases and
grade 3 in 17 cases. ASCD was possible to be assessed in
124 cases that had sufficient amount of evaluable non-
fibrotic lung tissue. 75 cases showed grade 1 and 43 cases
showed grade 2 of ASCD. FVC % within 6 months prior
to biopsy was available in 146 patients and ranged from
26 to 109% of predicted value. Fibrosis score was possible
to assess in 140 patients ranged from 10 to 195. 119
patients underwent transthoracic echocardiography with
available RVSP that ranged from 24 to 114 mmHg. The
numbers of patients having available RVSP data as well as
iron deposition, ASCD, fibrosis score and FVC% were
114, 91, 116 and 113 cases, each.
The median interval between echocardiography and
surgical lung biopsy was 14.5 days (range, 0-826 days);
75.4% of the echocardiograms had been performed
within 3 months of the surgical lung biopsy. Left ventric-
ular function was graded normal (score 0) in 93.2% and
mildly impaired or enlarged (score 1) in 6.8% of patients.
L e f t  a t r i a l  s i z e  w a s  n o r m a l  ( s c o r e  0 )  i n  5 2 . 5 % ,  m i l d l y
enlarged (score 1) in 31.4%, moderately enlarged (score 2)
in 11.9% or severely enlarged (score 3) in 4.2% patients.
Right ventricular function was normal (score 0) in 78%,
mildly impaired or enlarged (score 1) in 11%, moderately
impaired or enlarged in 8.5% and severely impaired or
enlarged (score 3) in 2.5% of patients. There was signifi-
cant association neither between iron deposition and left
ventricular function, left atrial size or right ventricular
function (Spearmans' correlation coefficients -0.06 [p =
0.55], 0.18 [p = 0.06], and 0.15 [p = 0.12], respectively),
nor between ASCD and left ventricular function, left
Figure 1 A case showing grade 1 alveolar septal capillary density 
(ASCD) (A and B) without any increase in endothelial cells in the 
alveolar septa (A: hematoxylin eosin stain; B: anti CD34 immu-
nostain, ×200 original magnification). A case showing grade 2 
ASCD (C and D) with a marked increase in endothelial cells (C: hema-
toxylin eosin stain; D: anti CD34 immunostain, ×200 original magnifica-
tion).
Figure 2 A case with grade 3 iron deposition mainly involving the 
alveolar spaces (Prussian blue iron stain, ×200 original magnifica-
tion).Kim et al. Respiratory Research 2010, 11:37
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atrial size or right ventricular function (Spearmans' cor-
relation coefficients -0.11 [p = 0.31], -0.10 [p = 0.33], and
0.16 [p = 0.14], respectively).
On univariate analysis, there was a significant correla-
tion between RVSP and degree of iron deposition as well
as ASCD (p < 0.001, both). The change in FVC% was also
significantly associated with RVSP by univariate analysis
(p = 0.034), but fibrosis score did not show correlation
with RVSP by univariate analysis (p = 0.75) (Table 2).
Multivariable regression analysis investigating the asso-
ciation of RVSP with iron deposition, ASCD, fibrosis
score and FVC% showed that iron deposition maintained
the statistically significant association with RVSP (p =
0.02) (Table 2). ASCD did not show a significant associa-
tion but a trend was observed on this multivariate analy-
sis (p = 0.073) (Table 3). Three initial models were fit with
iron deposition, fibrosis score, and the iron deposition by
fibrosis score interaction; ASCD, fibrosis, and the ASCD
by fibrosis score interaction; FVC%, fibrosis score, and
FVC% by fibrosis interaction. There was no interaction
between iron deposition and fibrosis score (p = 0.130),
nor an interaction between ASCD and fibrosis score (p =
0.22), nor an interaction between FVC% and fibrosis
score (p = 0.92). Following this the above multivariable
model was fit.
Discussion
PH has been a focus of new investigations due to its
potential prognostic and therapeutic implications in IPF
patients. Recent studies have demonstrated that severe
PH in IPF can occur in the absence of advanced pulmo-
nary dysfunction or hypoxemia [3,15]. As more specific
and effective treatment for PH has become available,
early diagnosis and treatment of PH could improve the
prognosis in the subset of IPF with PH. Right heart cathe-
terization is the gold standard for the diagnosis of PH but
is invasive and not widely used in IPF patients. We sought
to identify the histologic features that could potentially be
the predictors of PH or indicators for further clinical
work-up in IPF patients, mainly using the sections of sur-
gical lung biopsies that had been performed for the diag-
nosis.
It has been thought that PH in IPF develops as a conse-
quence of progressive fibrosis and obliteration of alveoli
with vascular changes occurring secondary to the reduc-
tion of the pulmonary vascular bed [3,16]. However, this
postulation has been questioned as many investigators
explored the association of the remodeling of pulmonary
vessel in PH associated with IPF. We also have noted that
non-fibrotic areas in some lung biopsies of interstitial
lung disease (ILD) cases show extraordinary capillary
Table 1: Demographics of patients
Variable N %
Age
Mean ± standard deviation 64.4 ± 10.1
Median; range 66; 28-87
Gender
Female 62 40.3
Male 92 59.7
Table 2: Univariate analysis of iron deposition, ASCD, fibrosis score and FVC% with RVSP
Variable Parameter estimate P
Iron deposition (n = 114) < 0.001
Grade 0 Reference
Grade 1 3.0
Grade 2 6.6
Grade 3 18.6
ASCD (n = 91) < 0.001
Grade 1 (ASCD < 1.5) -12.7
Grade 2 (ASCD ≥ 1.5) Reference
Fibrosis score (n = 116) 0.01 0.75
FVC% (n = 113) -0.2 0.034Kim et al. Respiratory Research 2010, 11:37
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proliferations that were accompanied by clinical PH; they
mimicked the changes of pulmonary capillary heman-
giomatosis (PCH) with pulmonary veno-occlusive disease
(PVOD)-like features in the background (unpublished
observations). These cases also had hemosiderin deposi-
tions and muscularization of pulmonary arterioles in
addition to PCH- or PVOD-like changes, which comprise
the features of postcapillary PH. Since the distribution of
fibrosis in usual interstitial pneumonia, histopathologic
manifestation of IPF, coincides with the distribution of
pulmonary veins and venules in the interlobular and
interstitial septa of peripheral alveolar acini, these find-
ings could be simply caused by fibrosis. However, one can
also postulate that the fibrogenic stimuli involved in IPF
might also affect remodeling of postcapillary pulmonary
vessels, causing PVOD-like condition.
This led us to hypothesize that these histologic changes
may be associated with PH in IPF, possibly independent
of lung function or fibrosis. T o test this hypothesis, we
attempted to measure several histologic parameters in
the surgical lung biopsies in the cohort of IPF patients
diagnosed over a recent 10-year-period. It was very diffi-
cult to quantify these histologic features in an objective,
systematic manner. Among these, we found that PCH-
like changes by counting the number of endothelial cells
on CD34 immunostaining (expressed as ASCD) and
hemosiderin deposition assessed by iron stain were most
feasible for quantitation in the exploration of this hypoth-
esis. Although smoker's pigments in the alveolar mac-
rophages can mimic hemosiderin, they are typically
dustier and distinguishable from refractile, chunky iron
pigments.
In our study, iron deposition in IPF was associated with
higher RVSP independently of the degree of overall fibro-
sis or pulmonary function impairment as assessed by
fibrosis score on the HRCT scan and FVC on PFT,
respectively. Though not reaching the statistical signifi-
cance, ASCD also showed a trend of association with
RVSP on multivariate analysis. FVC% was associated with
RVSP on univariate analysis but not on multivariate anal-
ysis, however. We analyzed the RVSP data as categorical
variable by assigning the value of ≥ 40 mmHg as positive
and <40 mmHg as negative for pulmonary hypertension.
As was in the analysis using RVSP value as continuous
variable, iron score 3 and ASCD score ≥ 1.5 showed the
similar findings in both univariate and multivariate analy-
ses (data not shown).
Our study demonstrated HRCT fibrosis score did not
show any association with RVSP either on univariate or
multivariate analysis, reiterating the conclusion of a pre-
vious study; a cross-sectional study of 65 patients with
advanced IPF revealed that the extent of pulmonary
fibrosis determined on chest HRCT did not predict PH in
advanced IPF patients [15]. A recent clinical study also
has reported that there is a poor correlation between lung
f u n c t i o n  m e a s u r e s  a n d  P H  i n  I P F  p a t i e n t s ,  s u g g e s t i n g
that factors other than parenchymal fibrosis may play a
role in the pathogenesis of PH [17].
Histopathologic findings of pulmonary vessels in IPF
w e r e  r e p o r t e d  m o s t l y  b a s e d  o n  v a s c u l a r  a b n o r m a l i t i e s
seen in scarred areas and consist of intimal hyperplasia,
fibrosis, and reduplication of the inner elastic lamina in
the small muscular pulmonary arteries in fibrotic lobules
[18]. However, Colombat et al reported the vascular
changes in the architecturally preserved lung tissues as
intimal proliferation and fibrosis causing occlusion of
venules and small pulmonary veins involving 65% of
explant lung specimens from their 26 end-stage IPF cases
[16]. Other studies reported increased capillary density
and angiogenesis in nonfibrotic lung tissues [19-21]. A
greater angiogenic response to IL-8 was detected in UIP
lung tissue than in control tissue [22]. A study shows that
TGF-beta1-induced and hypoxia-induced VEGF expres-
sion by human lung epithelial cells may promote neovas-
Table 3: Multivariate analysis of iron deposition, ASCD, fibrosis and FVC% with RVSP
Variable Parameter estimate p
Iron deposition 0.02
Grade 0 Reference
Grade 1 0.4
Grade 2 5.0
Grade 3 14.5
ASCD 0.073
Grade 1 (ASCD < 1.5) -6.7
Grade 2 (ASCD ≥ 1.5) reference
Fibrosis -0.01 0.83
FVC% -0.12 0.23Kim et al. Respiratory Research 2010, 11:37
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cularization, thereby contributing to the repair of injuries
to the lung endothelium [23].
The existence of neovascularization in IPF was origi-
nally described in 1963 by Turner-Warwick [24]. Hetero-
geneous vascular remodeling in UIP has been reported by
Ebina et al, who also identified increased alveolar septal
vascular densities in less fibrotic areas [19]. Several other
authors have reported the abnormal vascular remodeling
in ILDs although their findings in the literature seemed to
be somewhat conflicting [20,25,26]. Chronic inflamma-
tion is often associated with fibroproliferation and neo-
vascularization histologically [27]. Inflammation and
angiogenesis are also closely related events and tempo-
rally coincide [27]. It is possible that neovascularization
in ILD is at least partly due to the overlapping properties
of many inflammatory, fibrogenic and angiogenic cytok-
ines involved in the pathogenesis of ILDs. A previous
study has postulated that an imbalance between the levels
of angiogenic and angiostatic chemokines may result in
aberrant angiogenesis in both animal models and tissue
specimens from IPF patients [28].
A recent clinicopathologic study reported that occlu-
sive venopathy in nonfibrotic lung tissue was observed in
65% of their 26 explanted lungs from end-stage IPF
patients [16]. As in our cases, this study also demon-
strated that most of these patients had increased alveolar
capillary densities with PCH-like changes, hemosiderin
depositions and muscularized arterioles [16]. Their sta-
tistical analysis showed that the mean pulmonary artery
pressure (PAP) correlated with the macroscopic extent of
fibrosis, but not with occlusive venopathy [16]. However,
this study only included the explanted lungs that would
represent the end-stage fibrosis requiring lung transplan-
tation. On the other hand, our cases were mainly com-
posed of sur gical biopsies for diagnostic purposes tha t
w oul d i nc lude  bot h ea r l ie r as we l l as la t e s tag e  o f  IPF
cases. This could have been a factor for the differing
results between the two studies.
Our retrospective study is mainly limited by the lack of
confirmatory right heart catheterization. We used the
hemodynamic data obtained by Doppler echocardiogra-
phy that affords a reasonably good correlation with the
right hear catheterization data [29]. One may suspect the
iron deposition or increased ASCD in IPF is non-specific,
possibly secondary to left heart disease or age-related. In
the present study, however; neither echocardial parame-
ters for left heart function nor age of the patients corre-
lated with iron deposition or ASCD, which would argue
against such possibilities. We sampled all remaining gross
specimens stored in the surgical pathology files for a
complete microscopic examination of existing tissues for
all surgical biopsies. We also thoroughly examined
explanted lungs using multiple representative sections.
Some cases still did not have sufficient microscopic fields
to assess the changes in nonfibrotic lung tissues, however.
We used both FVC% and HRCT fibrosis score to assess
the severity of IPF, which should have given a more com-
prehensive evaluation for the severity than the assess-
ment based on the given biopsy materials as used in a
previous study [19].
In summary, our study demonstrated that iron deposi-
tion and ASCD, histologic features associated with post-
capillary remodeling, are also associated with RVSP in a
non-selected cohort of IPF patients. Iron deposition and
ASCD were associated or had a trend independent of the
severity of disease assessed by FVC% and HRCT. These
findings were not related to age or left heart function
assessed by echocardiography.
Conclusion
Our results suggest iron deposition and ASCD as poten-
tially useful morphologic indicators that could lead to the
timely diagnosis of PH in IPF patients with appropriate
further clinical work-up. This study is limited by the lack
of right heart catheterization and further studies would
be needed to confirm our finding.
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